Timothy Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy Jang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Charles Meltzer
The George Washington University School of Medicine and Health Sciences, Department of Emergency Medicine, Washington, DC, USA
1 shared publication - Angela L. Hewlett
Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska 68198
1 shared publication - Angela M. Mills
Department of Emergency Medicine Columbia University College of Physicians and Surgeons New York New York USA
1 shared publication - Caroline E. Freiermuth
Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
1 shared publication - Christopher R. Carpenter
Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Edmond Anderson Hooker
Department of Health Services Administration, Xavier University, Cincinnati, OH, USA
1 shared publication
Latest Publications
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1293. Efficacy of Doxycycline in Staphylococcal Prosthetic Joint Infection Treated with Debridement, Antibiotics and Implant Retention (DAIR) or Revision with Destination Spacer Placement
Prosthetic joint infection (PJI) is common, limb-threatening, and often warrants extended antibiotic durations. Intravenous (IV) glycopeptide, lipopeptide, and beta-lactam antibiotics have been the de facto US standard of care for staphylococcal PJI for decades, while the preponderance of (mostly European) published clinical data for PJI involves fluoroquinolone and rifampin combinations. However, these antibiotic strategies carry substantial adverse effects. In contrast, tetracyclines are less-studied for treatment of staphylococcal PJIs, but offer ease of administration and a favorable side effect profile. We retrospectively evaluated the characteristics and outcomes of patients with staphylococcal PJI treated with doxycycline from March 2019 to April 2021 who received some period of outpatient parenteral antibiotic therapy (OPAT) and were included in our medical center’s OPAT database. We included patients with hip, knee, or shoulder PJIs managed with either debridement, antibiotics and implant retention (DAIR) or revision to a permanent “destination” spacer who received doxycycline within the first 12 weeks of therapy. Diagnosis of staphylococcal PJI was based on the documentation of the treating ID team plus identification of staphylococci in surgical tissue or synovial fluid cultures. Our primary outcome of interest was treatment failure, defined as reoperation for infection in the affected joint within one year of initial surgery. Of 24 patients switched to doxycycline after a mean 42 days, 17 underwent DAIR and 7 had destination spacers placed. 15 of 17 patients (88.2%) who underwent DAIR and 7 of 7 patients (100%) who received destination spacers remained free of treatment failure at one year; two patients had recurrent infections and none died. These findings suggest that doxycycline is a safe and efficacious option for treatment of PJI. A key limitation of this study is patient identification via the OPAT database, meaning patients with short IV lead-in therapy (i.e. switch to PO at discharge) were not included, and that the efficacy of doxycycline is likely exaggerated by immortal time. Angela Hewlett, MD, MS, Forcast Orthopedics: Advisor/Consultant|Mapp Biopharmaceutical: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1293. Efficacy of Doxycycline in Staphylococcal Prosthetic Joint Infection Treated with Debridement, Antibiotics and Implant Retention (DAIR) or Revision with Destination Spacer Placement
Prosthetic joint infection (PJI) is common, limb-threatening, and often warrants extended antibiotic durations. Intravenous (IV) glycopeptide, lipopeptide, and beta-lactam antibiotics have been the de facto US standard of care for staphylococcal PJI for decades, while the preponderance of (mostly European) published clinical data for PJI involves fluoroquinolone and rifampin combinations. However, these antibiotic strategies carry substantial adverse effects. In contrast, tetracyclines are less-studied for treatment of staphylococcal PJIs, but offer ease of administration and a favorable side effect profile. We retrospectively evaluated the characteristics and outcomes of patients with staphylococcal PJI treated with doxycycline from March 2019 to April 2021 who received some period of outpatient parenteral antibiotic therapy (OPAT) and were included in our medical center’s OPAT database. We included patients with hip, knee, or shoulder PJIs managed with either debridement, antibiotics and implant retention (DAIR) or revision to a permanent “destination” spacer who received doxycycline within the first 12 weeks of therapy. Diagnosis of staphylococcal PJI was based on the documentation of the treating ID team plus identification of staphylococci in surgical tissue or synovial fluid cultures. Our primary outcome of interest was treatment failure, defined as reoperation for infection in the affected joint within one year of initial surgery. Of 24 patients switched to doxycycline after a mean 42 days, 17 underwent DAIR and 7 had destination spacers placed. 15 of 17 patients (88.2%) who underwent DAIR and 7 of 7 patients (100%) who received destination spacers remained free of treatment failure at one year; two patients had recurrent infections and none died. These findings suggest that doxycycline is a safe and efficacious option for treatment of PJI. A key limitation of this study is patient identification via the OPAT database, meaning patients with short IV lead-in therapy (i.e. switch to PO at discharge) were not included, and that the efficacy of doxycycline is likely exaggerated by immortal time. Angela Hewlett, MD, MS, Forcast Orthopedics: Advisor/Consultant|Mapp Biopharmaceutical: Grant/Research Support
- 11 May 2022
- Published by Wiley in Academic Emergency Medicine
- Vol. 29 (5) , 526-560
Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE‐2): Low‐risk, recurrent abdominal pain in the emergency department
This second Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) from the Society for Academic Emergency Medicine is on the topic “low‐risk, recurrent abdominal pain in the emergency department.” The multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding four priority questions for adult emergency department patients with low‐risk, recurrent, undifferentiated abdominal pain. The intended population includes adults with multiple similar presentations of abdominal signs and symptoms recurring over a period of months or years. The panel reached the following recommendations: (1) if a prior negative computed tomography of the abdomen and pelvis (CTAP) has been performed within 12 months, there is insufficient evidence to accurately identify populations in whom repeat CTAP imaging can be safely avoided or routinely recommended; (2) if CTAP with IV contrast is negative, we suggest against ultrasound unless there is concern for pelvic or biliary pathology; (3) we suggest that screening for depression and/or anxiety may be performed during the ED evaluation; and (4) we suggest an opioid‐minimizing strategy for pain control.EXECUTIVE SUMMARY: The GRACE‐2 writing group developed clinically relevant questions to address the care of adult patients with low‐risk, recurrent, previously undifferentiated abdominal pain in the emergency department (ED). Four patient‐intervention‐comparison‐outcome‐time (PICOT) questions were developed by consensus of the writing group, who performed a systematic review of the literature and then synthesized direct and indirect evidence to formulate recommendations, following GRADE methodology. The writing group found that despite the commonality and relevance of these questions in emergency care, the quantity and quality of evidence were very limited, and even fundamental definitions of the population and outcomes of interest are lacking. Future research opportunities include developing precise and clinically relevant definitions of low‐risk, recurrent, undifferentiated abdominal pain and determining the scope of the existing populations in terms of annual national ED visits for this complaint, costs of care, and patient and provider preferences.
- 11 May 2022
- Published by Wiley in Academic Emergency Medicine
- Vol. 29 (5) , 526-560
Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE‐2): Low‐risk, recurrent abdominal pain in the emergency department
This second Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) from the Society for Academic Emergency Medicine is on the topic “low‐risk, recurrent abdominal pain in the emergency department.” The multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding four priority questions for adult emergency department patients with low‐risk, recurrent, undifferentiated abdominal pain. The intended population includes adults with multiple similar presentations of abdominal signs and symptoms recurring over a period of months or years. The panel reached the following recommendations: (1) if a prior negative computed tomography of the abdomen and pelvis (CTAP) has been performed within 12 months, there is insufficient evidence to accurately identify populations in whom repeat CTAP imaging can be safely avoided or routinely recommended; (2) if CTAP with IV contrast is negative, we suggest against ultrasound unless there is concern for pelvic or biliary pathology; (3) we suggest that screening for depression and/or anxiety may be performed during the ED evaluation; and (4) we suggest an opioid‐minimizing strategy for pain control.EXECUTIVE SUMMARY: The GRACE‐2 writing group developed clinically relevant questions to address the care of adult patients with low‐risk, recurrent, previously undifferentiated abdominal pain in the emergency department (ED). Four patient‐intervention‐comparison‐outcome‐time (PICOT) questions were developed by consensus of the writing group, who performed a systematic review of the literature and then synthesized direct and indirect evidence to formulate recommendations, following GRADE methodology. The writing group found that despite the commonality and relevance of these questions in emergency care, the quantity and quality of evidence were very limited, and even fundamental definitions of the population and outcomes of interest are lacking. Future research opportunities include developing precise and clinically relevant definitions of low‐risk, recurrent, undifferentiated abdominal pain and determining the scope of the existing populations in terms of annual national ED visits for this complaint, costs of care, and patient and provider preferences.
- 6 February 2019
- Published by Springer Nature
- p. 213-215
Consultant Corner: Gallbladder Disease
- 1 January 2004
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 43 (1) , 139-140
Droperidol and the black box warning
- 1 January 2004
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 43 (1) , 139-140
Droperidol and the black box warning